Neratinib is a multi-targeted, irreversible tyrosine kinase inhibitor (TKI) oral drug which targets the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases.
Neratinib is being studied in the neoadjuvant, adjuvant and advanced settings in HER2/ErbB2 positive breast cancer.
Pfizer said it will award payments upon Puma’s achievement of certain development milestones for neratinib, as well as royalty payments for any sales of neratinib.